News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 4, 2020 Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
May 28, 2020 Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
May 21, 2020 Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 14, 2020 Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
May 8, 2020 Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
May 7, 2020 Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
April 29, 2020 Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
April 28, 2020 Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
April 6, 2020 Paul Fonteyne Joins Apellis Board of Directors
February 27, 2020 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results